Iceland· IS-IS/1/26/001/08
Selexipag STADA
A selexipag product containing selexipagum inn, registered in Iceland by STADA Arzneimittel AG. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Selexipag is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Selexipag · ATC B01AC27
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of selexipag costs, country by country.
Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selexipag · price per daily dose (1.8 mg)
USD · FX 28 Sept 2026
- IT Italy$1232.99
- CH Switzerland$809.99
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Selexipagum INN
- Manufacturer
- STADA Arzneimittel AG
- Country
- Iceland (IS)
- ATC code
- B01AC27
- ATC class
- Selexipag
- Defined daily dose
- 1.8 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
237 interactions on record for selexipag.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selexipag · interactions on record
237 records
- 1 severe
- 232 moderate
- 4 minor
Most severe, free to view
- GemfibrozilC10AB04severe
- PapaverineA03AD01moderate
- MannitolA06AD16moderate
- GlycerolA06AX01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selexipag in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsSelexipag Abdi 1.000 microgram filmomhulde tablettenAbdi Farma GmbH
- SwedenSelexipag Accord 1000 mikrogram Filmdragerad tablettAccord Healthcare B.V.
- CzechiaSELEXIPAG ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- PolandSelexipag AccordAccord Healthcare Polska Sp. z o.o.
- SpainSELEXIPAG ACCORD 1000 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- United StatesSelexipagZydus Pharmaceuticals (USA) Inc.
- IrelandSelexipag Accord 1 000 microgram film-coated tabletsAccord Healthcare Ireland Ltd.
- FinlandUptraviJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Selexipag Ratiopharm
- Cyprus · Selexipag Accord
- Denmark · Selexipag Accord, Selexipag Stada
- Estonia · Selexipag Stada
- Spain · Selexipag Accord, Selexipag Stada
- Greece · Xipeno
- Croatia · Seleksipag Accord
- Ireland · Selexipag Accord, Selexipag Clonmel
- Italy · Selexipag Accord, Selexipag Eg
- Liechtenstein · Uptravi
- Lithuania · Selexipag Stada
- Latvia · Selexipag Stada
- Malta · Selexipag Clonmel
- Netherlands · Seleksipag Accord, Selexipag Abdi
- Norway · Selexipag Accord, Selexipag Stada
- Poland · Selexipag, Selexipag Accord
- Portugal · Selexipag Accord, Selexipag Teva
- Sweden · Selexipag, Selexipag Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f36f522d-214b-4b87-acbd-9e83d1e9c364 GET /v1/drugs/f36f522d-214b-4b87-acbd-9e83d1e9c364?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "B01AC27",
"marketed": false,
"strength": "1600 míkróg",
"ma_number": "IS/1/26/001/08",
"substance": "Selexipagum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í hjartasjúkdómum og sérfræðinga í lungnasjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "46024"
}See everything about selexipag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.